...
首页> 外文期刊>Scientific reports. >Human heart valve-derived scaffold improves cardiac repair in a murine model of myocardial infarction
【24h】

Human heart valve-derived scaffold improves cardiac repair in a murine model of myocardial infarction

机译:人体心脏瓣膜衍生的脚手架改善了心肌梗死的小鼠模型中的心脏修复

获取原文

摘要

Cardiac tissue engineering using biomaterials with or without combination of stem cell therapy offers a new option for repairing infarcted heart. However, the bioactivity of biomaterials remains to be optimized because currently available biomaterials do not mimic the biochemical components as well as the structural properties of native myocardial extracellular matrix. Here we hypothesized that human heart valve-derived scaffold (hHVS), as a clinically relevant novel biomaterial, may provide the proper microenvironment of native myocardial extracellular matrix for cardiac repair. In this study, human heart valve tissue was sliced into 100?μm tissue sheet by frozen-sectioning and then decellularized to form the hHVS. Upon anchoring onto the hHVS, post-infarct murine BM c-kit+ cells exhibited an increased capacity for proliferation and cardiomyogenic differentiation in vitro. When used to patch infarcted heart in a murine model of myocardial infarction, either implantation of the hHVS alone or c-kit+ cell-seeded hHVS significantly improved cardiac function and reduced infarct size; while c-kit+ cell-seeded hHVS was even superior to the hHVS alone. Thus, we have successfully developed a hHVS for cardiac repair. Our in vitro and in vivo observations provide the first clinically relevant evidence for translating the hHVS-based biomaterials into clinical strategies to treat myocardial infarction.
机译:使用具有或不具有干细胞疗法组合的生物材料的心脏组织工程提供了修复梗塞心脏的新选择。然而,生物材料的生物活性仍有待优化,因为目前可用的生物材料不会模拟生物化学成分以及本地心肌细胞外基质的结构性。在这里,我们假设人体心脏瓣膜衍生的支架(HHV)作为临床相关的新型生物材料,可以为心脏修复提供本地心肌细胞外基质的适当微环境。在该研究中,通过冷冻切片切割人的心脏瓣膜组织将100μm薄纸片切成100μm薄膜片,然后脱粗化以形成HHV。在锚固到HHV上时,梗死后鼠BM C-kit +细胞表现出在体外增殖和心肌分化的增加能力。当用于在心肌梗死的小鼠模型中嵌入梗塞的心脏时,单独植入HHV或C-kit +细胞接种HHVs显着提高了心脏功能和减少的梗塞尺寸;虽然C-kit +细胞种子HHVs甚至优于单独的HHV。因此,我们已经成功开发了一种用于心脏修复的HHV。我们的体外和体内观察提供了第一个将基于HHV的生物材料翻译成临床策略来治疗心肌梗塞的第一个临床相关证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号